Biohaven Secures Global Licensing Deal with SK Biopharmaceuticals for Kv7 Ion Channel Platform and Lead Epilepsy Candidate Opakalim, Including $400M Upfront

August 30, 2026

PR Newswire Global

Overview

Biohaven and SK Biopharmaceuticals have signed a strategic global licensing and co-development agreement for a novel Kv7 ion channel platform, including its lead candidate Opakalim for focal epilepsy. Under the terms, Biohaven receives an upfront payment of $400 million, with eligibility for up to $150 million in development and regulatory milestones, plus royalties on global net sales of Opakalim. Opakalim is currently in Phase 2/3 clinical development for epilepsy, and this collaboration holds the potential to deliver a new treatment option for patients with difficult-to-treat epilepsy, accelerating innovation in neurological disease.

In Depth

Key Findings

Biohaven and SK Biopharmaceuticals have entered into a global licensing and co-development agreement for a novel Kv7 ion channel platform, featuring Opakalim as its lead candidate for epilepsy. This significant deal includes an upfront payment of $400 million to Biohaven, with potential additional payments of up to $150 million upon the achievement of development and regulatory milestones. Biohaven is also eligible for royalties on the global net sales of Opakalim. Currently in Phase 2/3 development for focal epilepsy, this partnership promises new hope for patients suffering from difficult-to-treat epilepsy.

Technical / Clinical Details

Kv7 ion channels play a critical role in regulating neuronal hyperexcitability and are emerging as important therapeutic targets for neurological disorders such as epilepsy. Opakalim is designed to modulate these Kv7 ion channels, thereby enhancing neuronal stability and suppressing the occurrence of epileptic seizures. Current Phase 2/3 clinical trials are evaluating the safety and efficacy of Opakalim in patients with focal epilepsy, with particular anticipation for its effects in those who have not responded adequately to existing medications. The platform’s potential extends beyond epilepsy, with possible applications in other neurological conditions.

Background & Context

Epilepsy is a chronic neurological disorder affecting millions worldwide, and a significant number of patients with focal epilepsy do not achieve adequate seizure control with current anti-epileptic drugs. In this context of high unmet medical need, the development of therapeutic agents with novel mechanisms of action, such as those targeting Kv7 ion channels, is highly prioritized. The collaboration between Biohaven and SK Biopharmaceuticals aims to combine their respective expertise and resources to accelerate the development process and bring innovative treatments to patients more quickly.

Strategic Significance & Outlook

Should Opakalim successfully progress through clinical development and gain regulatory approval, it has the potential to introduce a new paradigm in the treatment of focal epilepsy. Its novel mechanism of action could offer substantial benefits for patients with resistance to existing drugs or those facing challenges with current side effect profiles. This global partnership is expected to intensify competition in the neurological disease market and drive further research into broader applications of the Kv7 ion channel platform across various neurological conditions. In the long term, this could be seen as a successful model for technology licensing agreements in the pharmaceutical industry.

Source: https://www.prnewswire.com/news-releases/biohaven-and-sk-biopharmaceuticals-enter-into-strategic-global-licensing-agreement-for-novel-kv7-ion-channel-platform-and-opakalim-lead-candidate-for-epilepsy-302860299.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.